Chadds Ford, PA www.endo.com. Therapeutic Areas Pain- Chronic Pain- Acute Pain- Neuropathic Neurology, Oncology.
Company Description - Endo Pharmaceuticals Holdings Inc was established in 1920 as a specialty pharmaceutical company focused on developing branded and generic treatments for pain. Flagship products include the Lidoderm patch and Percocet. In July 2004, Endo obtained exclusive rights to market Vernalis‘ [menstrually associated] migraine therapy, frovatriptan. They currently hold the rights to commercialize EpiCept’s LidoPAIN BP for acute low back pain, and have 8 products in clinical development. Endo’s 2006 sales were $909.7M USD. The company currently has approximately 1000 employees.
Transaction Rationale– Endo seeks & PPC can provide: Additional validated pain products for a primarily late stage pipeline. Secondary indications may be of interest to Endo, as they are looking to expand into related markets.
PPC seeks & Endo can provide: US presence and access to US stock exchange, Phase II & III products, experience developing topical analgesic treatment, strong financial position.
5 June 2007